SJS Investment Consulting Inc. Sells 152 Shares of Cencora, Inc. (NYSE:COR)

SJS Investment Consulting Inc. decreased its stake in Cencora, Inc. (NYSE:COR) by 15.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 847 shares of the company’s stock after selling 152 shares during the period. SJS Investment Consulting Inc.’s holdings in Cencora were worth $190,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Linden Thomas Advisory Services LLC lifted its position in Cencora by 15.9% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 9,012 shares of the company’s stock worth $2,025,000 after purchasing an additional 1,239 shares during the period. Dynamic Advisor Solutions LLC boosted its position in shares of Cencora by 23.7% during the 4th quarter. Dynamic Advisor Solutions LLC now owns 1,442 shares of the company’s stock valued at $324,000 after acquiring an additional 276 shares in the last quarter. Fifth Third Bancorp raised its position in Cencora by 6.5% in the fourth quarter. Fifth Third Bancorp now owns 19,224 shares of the company’s stock worth $4,319,000 after purchasing an additional 1,167 shares in the last quarter. Pflug Koory LLC lifted its stake in Cencora by 6.9% during the fourth quarter. Pflug Koory LLC now owns 1,160 shares of the company’s stock worth $261,000 after purchasing an additional 75 shares during the period. Finally, Cottonwood Capital Advisors LLC boosted its holdings in Cencora by 95.5% during the fourth quarter. Cottonwood Capital Advisors LLC now owns 1,750 shares of the company’s stock valued at $393,000 after purchasing an additional 855 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.2 %

Shares of COR opened at $248.45 on Friday. The firm has a market capitalization of $48.02 billion, a price-to-earnings ratio of 33.08, a PEG ratio of 1.54 and a beta of 0.49. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $253.27. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The business’s fifty day moving average price is $237.51 and its two-hundred day moving average price is $234.66.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a dividend of $0.55 per share. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.89%. The ex-dividend date was Friday, November 15th. Cencora’s payout ratio is currently 29.29%.

Wall Street Analyst Weigh In

Several research firms recently commented on COR. Barclays raised their target price on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Robert W. Baird lifted their price objective on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Wells Fargo & Company dropped their target price on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research report on Friday, December 13th. Mizuho started coverage on shares of Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target on the stock. Finally, Leerink Partners dropped their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a report on Monday, October 7th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $277.00.

Insider Activity

In other news, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 73,187 shares of company stock valued at $17,790,912. 15.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.